Compliance Rate

Compliance Rate 0%
Compliant submissions 0
Incompliant submissions 0
Total trials 0

My Organizations' Clinical Trials

Showing 50 of 344 entries
View as:

FOLFOX Combined With Durvalumab (MEDI4736), Bevacizumab, and Stereotactic Body Radiotherapy in Sequential Treatment of Potentially Resectable Locally Advanced Hepatocellular Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT07012798 Org: User:
Start: 06/30/25 End: 12/31/26 Due: 12/31/27

Efficacy and Safety of Sintilimab Combined With Regorafenib and Cetuximab / Sintilimab Combined With Regorafenib in Posterior Line Therapy of Advanced Colorectal Cancer (Regosinti)

Phase: N/A Priority: Normal
NCT ID: NCT04745130 Org: User:
Start: 03/01/21 End: 01/31/24 Due: 01/31/25

Cryoablation Combined With Tislelizumab and Chemotherapy as Neoadjuvant and Adjuvant Therapy in Resectable Stage II-IIIB NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT06939127 Org: User:
Start: 04/01/25 End: 05/31/27 Due: 05/31/28

Study of Chemotherapy Combination With Autologous Cytokine-Induced Killer Cell Immunotherapy to Treat Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01631357 Org: User:
Start: 12/31/14 End: 12/31/18 Due: 12/31/19

Mirtazapine Plus Gemcitabine Versus Gemcitabine in Metastasis Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01598584 Org: User:
Start: 06/30/12 End: 12/31/15 Due: 12/31/16

Safety and Efficacy of XELOX Combined With Sintilimab and Lenvatinib in Advanced AFP-positive Gastric Cancer Patients

Phase: N/A Priority: Normal
NCT ID: NCT06383559 Org: User:
Start: 12/01/23 End: 09/01/26 Due: 09/01/27

Multi-institutional Analysis of Survival and Recurrence Patterns of Different Pathological Regression Types After Neoadjuvant Chemoradiotherapy or Radiotherapy for Esophageal Squamous Cell Carcinoma

Phase: N/A Priority: Normal
NCT ID: NCT06241079 Org: User:
Start: 03/31/03 End: 02/01/23 Due: 02/01/24

Pre-pectoral Breast Reconstruction With or Without Mesh

Phase: N/A Priority: Normal
NCT ID: NCT05888571 Org: User:
Start: 07/01/23 End: 12/31/26 Due: 12/31/27

Clinical Safety and Preliminary Efficacy of AAV-DC-CTL Treatment in Stage IV Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT01637805 Org: User:
Start: 05/31/12 End: 12/31/16 Due: 12/31/17

Mediastinal Lymph Node Dissection Versus Spared Mediastinal Lymph Node Dissection in Stage I GGN NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT04631770 Org: User:
Start: 05/01/22 End: 05/01/29 Due: 05/01/30

The Criteria for Lymph Node Sorting for Pathological Examination in Gastric Cancer

Phase: N/A Priority: Normal
NCT ID: NCT03478449 Org: User:
Start: 04/01/18 End: 12/30/20 Due: 12/30/21

Efficacy and Safety of Neo-CRT Followed Surgery Compared With Definitive CRT in Patients With Initial Unresectable ESO

Phase: N/A Priority: Normal
NCT ID: NCT04137679 Org: User:
Start: 11/01/19 End: 08/31/22 Due: 08/31/23

Effect of Different Anesthetics on the Change of Alarmins in Lung Cancer Patients Receiving Pulmonary Lobectomy

Phase: N/A Priority: Normal
NCT ID: NCT02916147 Org: User:
Start: 10/31/16 End: 01/31/19 Due: 01/31/20

AG Plus Nimotuzumab Sequential Irreversible Electroporation Ablation for Locally Advanced Pancreatic Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06938503 Org: User:
Start: 04/21/25 End: 04/28/28 Due: 04/28/29

AC-CHOP Versus CHOP in Patients With Previously Untreated PTCL-TFH

Phase: N/A Priority: Normal
NCT ID: NCT05678933 Org: User:
Start: 01/01/23 End: 12/01/29 Due: 12/01/30

Clinical Safety and Preliminary Efficacy of MAGE-A4 TCR Gene-Modified T Cells to Treat Malignant Tumors

Phase: N/A Priority: Normal
NCT ID: NCT01694472 Org: User:
Start: 07/31/12 End: 12/31/16 Due: 12/31/17

Study of Tislelizumab and Platinum-based Chemotherapy Combination With H1 Receptor Antagonist（Diphenhydramine）in Advanced and Metastatic Non-Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06704620 Org: User:
Start: 12/31/24 End: 11/30/27 Due: 11/30/28

Mecapegfilgrastim Prevents Neutropenia and Radiation Esophagitis

Phase: N/A Priority: Normal
NCT ID: NCT04171986 Org: User:
Start: 11/10/19 End: 10/31/21 Due: 10/31/22

Safety and Efficacy of Aumolertinib Combined With Anlotinib as 1st Line Treatment in Advanced Lung Cancer EGFR Mutation With TP53 Co-Mutation

Phase: N/A Priority: Normal
NCT ID: NCT05778149 Org: User:
Start: 03/31/23 End: 03/31/27 Due: 03/31/28

A Standardized Intervention to Improve the Management of Chemotherapy-induced Nausea and Vomiting

Phase: N/A Priority: Normal
NCT ID: NCT05792228 Org: User:
Start: 04/02/23 End: 10/12/23 Due: 10/12/24

A Multicenter, Prospective, Cohort Study of Trop-2 ADC Combination Therapy for Advanced Triple-negative Breast Cancer

Phase: N/A Priority: Normal
NCT ID: NCT06878625 Org: User:
Start: 12/06/24 End: 06/30/27 Due: 06/30/28

Study of Apatinib in Advanced Hepatocellular Carcinoma(HCC)

Phase: N/A Priority: Normal
NCT ID: NCT03046979 Org: User:
Start: 12/31/16 End: 12/31/18 Due: 12/31/19

A Phase II Trial to Compare Efficacy and Safety of CRT VS Neo-CRT in Patients Who Achieved CCR for Esophageal Cancer

Phase: N/A Priority: Normal
NCT ID: NCT02959385 Org: User:
Start: 09/30/16 End: 09/30/21 Due: 09/30/22

Study of Anlotinib Combined With Icotinib as the First-line Treatment in Patients With EGFR Mutation-positive NSCLC

Phase: N/A Priority: Normal
NCT ID: NCT03736837 Org: User:
Start: 12/01/18 End: 01/01/21 Due: 01/01/22

Concurrent Chemoradiotherapy Combination With Anlotinib for Limited-stage Small Cell Lung Cancer

Phase: N/A Priority: Normal
NCT ID: NCT04882033 Org: User:
Start: 05/07/21 End: 07/01/23 Due: 07/01/24